Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-02-22
2011-02-22
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07893095
ABSTRACT:
The invention relates to a method for the treatment or prevention of diseases or conditions associated with vascular endothelium dysfunction or liver injury comprising the administration to a patient in a need of such treatment or prevention of a therapeutically or prophylactically effective amount of a compound selected from the group consisting of:wherein R represents hydrogen atom, CH3, OH, pyridyl (C5H4N), 1-methylpyridyl (C5H4N—CH3) or pyridyl substituted with hydroxy group ((OH)C5H3N), and X represents a physiologically acceptable counterion.
REFERENCES:
patent: 2005/0267015 (2005-12-01), Batarseh
patent: 2006/0292252 (2006-12-01), Bhaskaran et al.
patent: WO 2004/009034 (2004-01-01), None
patent: WO 2005/067927 (2005-06-01), None
patent: WO 2006/024545 (2006-03-01), None
patent: WO 2006/136454 (2006-12-01), None
patent: WO 2007/103540 (2007-03-01), None
Stadler, R.H., et al., “Alkylpyridiniums. 1. Formation in Model Systems via Thermal Degradation of Trigonelline,”J. Agric. Food Chem. 50:1192-1199, American Chemical Society (2002).
Stadler, R.H., et al., “Alkylpyridiniums. 2. Isolation and Quantification in Roasted and Ground Coffees,”J. Agric. Food Chem. 50:1200-1206, American Chemical Society (2002).
Brooks, A.I., et al., “Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss,”Brain Res. 823:1-10, Elsevier/North-Holland Biomedical Press (1999).
Chacón, J.N., and Truscott, T.G., “Chemically induced Parkinson's disease. III: a study of a possible role of singlet molecular oxygen in Parkinson's disease,”J. Photochem. Photobiol. B. 11:261-267, Elsevier Sequoia (1991).
Cicchetti, F., et al., “Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats,”Neurobiol. Dis. 20:360-371, Academic Press (2005).
Lee, E.-S., and Charlton, C.G., “1-Methyl-4-phenyl-pyridinium increasesS-adenosyl-L-methionine dependent phospholipid methylation,”Pharmacol. Biochem. Behav. 70:105-114, Elsevier (2001).
Nagatsu, T., and Hirata, Y., “Inhibition of the Tyrosine Hydroxylase System by MPTP, 1-Methyl-4-phenylpyridinium Ion (MPP+) and the Structurally Related Compounds in vitro and in vivo,”Eur. Neurol. 26(supp 1):11-15, Karger (1987).
Rollema, H., et al., “In vivo Intracerebral Microdialysis Studies in Rats of MPP+Analogues and Related Charged Species,”J. Med. Chem. 33:2221-2230, American Chemical Society (1990).
Watanabe, K., et al., “Paraquat Depresses The Activity Of Angiotensin Converting Enzyme Expressed By Human Umbilical Vein Endothelial Cells In Culture,”Cell. Biol. Int. Rep. 15:205-210, International Federation for Cell Biology (1991).
Williams, A.C., et al., “Idiopathic Parkinson's Disease: A Genetic and Environmental Model,”Adv. Neurol. 80:215-218, Lippincott Williams & Wilkins (1999).
STN Database, Accession No. 1310 (1989:188332), “Anticholineesterase activity of alkaloid idomethylates” (accessed Jul. 2008).
STN Database, Accession No. 1313 (1969:448218), “Antiatherosclerotic drugs and fibrinolysis” (accessed Jul. 2008).
International Search Report for International Application No. PCT/IB2008/050666, mailed on Aug. 4, 2008, European Patent Office, Rijswijk, Netherlands.
Written Opinion for International Application No. PCT/IB2008/050666, mailed on Aug. 4, 2008, European Patent Office, Munich, Germany.
Chlopicki, S., et al.,“1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway,”Br J Pharmacol:152(2): 230-9 (Sep. 2007).
Grigor'eva, G.M. et al., “[Anticholinesterase activity of alkaloid iodomethylates,]”Dokl Akad Nauk SSSR:304(3):746-8 (Jan. 1989).
De Nicola, P. et al., “Antiatherosclerotic drugs and fibroinolysis” Int. Congr. Gerontol., Proc., 7th, vol. 2, pp. 441-443 publisher: Verlag Wien. Med. Akad., Vienna, Austria, 1966, pp. 441-443.
Adamus Jan
ChŁopicki Stefan
GĘbicki Jerzy
Marcinek Andrzej
Henley, III Raymond J
Sterne Kessler Goldstein & Fox P.L.L.C.
TRIGENDO sp. z o.o.
LandOfFree
Use of quaternary pyridinium compounds for vasoprotection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of quaternary pyridinium compounds for vasoprotection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of quaternary pyridinium compounds for vasoprotection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638182